购物车
- 全部删除
- 您的购物车当前为空
VER-246608 是ATP 竞争性的丙酮酸脱氢酶激酶抑制剂,对PDK-1,PDK-3,PDK-2,和PDK-4的IC50分别为 35 nM,40 nM,84 nM 和 91 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
VER-246608 是ATP 竞争性的丙酮酸脱氢酶激酶抑制剂,对PDK-1,PDK-3,PDK-2,和PDK-4的IC50分别为 35 nM,40 nM,84 nM 和 91 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 493 | 现货 | |
2 mg | ¥ 716 | 现货 | |
5 mg | ¥ 1,150 | 现货 | |
10 mg | ¥ 1,820 | 现货 | |
25 mg | ¥ 3,490 | 现货 | |
50 mg | ¥ 4,970 | 现货 | |
100 mg | ¥ 7,230 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,410 | 现货 |
产品描述 | VER-246608 is an effective and ATP-competitive inhibitor of pyruvate dehydrogenase kinase (IC50s: 35 nM, 40 nM, 84 nM, and 91 nM for PDK-1, PDK-3, PDK-2, and PDK-4, respectively).VER-246608 disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Consistent with a PDK mediated MOA, VER-246608 increased pyruvate dehydrogenase complex (PDC) activity, oxygen consumption and attenuated glycolytic activity. VER-246608 was found to potentiate the activity of doxorubicin. |
靶点活性 | PDK2:84 nM, PDK3:40 nM, PDK1:35 nM, PDK4:91 nM |
体外活性 | VER-246608 是一种新型且选择性的ATP竞争性PDK全异构体抑制剂。与PDK介导的MOA一致,VER-246608增加了丙酮酸脱氢酶复合体(PDC)活性、氧气消耗,并降低了糖酵解活性。然而,这些效应仅在D-葡萄糖耗尽条件下观察到,并且需要几乎完全消除PDC E1α亚单位的磷酸化。在标准培养基中,VER-246608对癌细胞的抗增殖作用较弱。 |
分子量 | 552.96 |
分子式 | C28H23ClF2N4O4 |
CAS No. | 1684386-71-7 |
Smiles | Cc1cnc(Cl)nc1-c1ccc(cc1)N(Cc1ccc(CNC(=O)C(F)F)cc1)C(=O)c1ccc(O)cc1O |
密度 | 1.414 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (90.42 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容